Xiaomei Ma, PhD
Professor of Epidemiology (Chronic Diseases)DownloadHi-Res Photo
Cards
Additional Titles
Co-Leader, Cancer Prevention and Control
Contact Info
Chronic Disease Epidemiology
PO Box 208034, 60 College Street
New Haven, CT 06520-8034
United States
About
Copy Link
Titles
Professor of Epidemiology (Chronic Diseases)
Co-Leader, Cancer Prevention and Control
Biography
Dr. Ma is Professor of Epidemiology at the Yale School of Public Health, and Co-Leader of the Cancer Prevention and Control Research Program at the Yale Comprehensive Cancer Center, Yale School of Medicine. She studies the etiology and health outcomes of different types of cancer, with a focus on pediatric cancer and malignancies of the hematopoietic system (e.g., leukemia, lymphoma, myelodysplastic syndromes, and myeloproliferative neoplasms). Her research has addressed the impact of immunological factors, chemical exposures, and genetic characteristics on the risk of cancer. In addition, she has assessed the patterns of care and cost implications of cancer screening and treatment in older adults.
Last Updated on May 09, 2025.
Appointments
Chronic Disease Epidemiology
ProfessorPrimary
Other Departments & Organizations
- Cancer Prevention and Control
- Chronic Disease Epidemiology
- Climate Change and Health
- COPPER Center
- K12 Calabresi Immuno-Oncology Training Program (IOTP)
- Yale Cancer Center
- Yale School of Public Health
- Yale Ventures
Education & Training
- PhD
- University of California at Berkeley (2001)
Research
Copy Link
Overview
Medical Research Interests
Chronic Disease; Epidemiology; Leukemia; Lymphoma; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasms
Public Health Interests
Cancer; Chronic Diseases; Aging; Maternal & Child Health; Health Policy
ORCID
0000-0001-9472-8032
Research at a Glance
Yale Co-Authors
Frequent collaborators of Xiaomei Ma's published research.
Publications Timeline
A big-picture view of Xiaomei Ma's research output by year.
Research Interests
Research topics Xiaomei Ma is interested in exploring.
Rong Wang, PhD
Nikolai Podoltsev, MD, PhD
Amer Zeidan, MBBS, MD
Scott Huntington, MD, MPH, MSc
Cary P Gross, MD
Nicole Deziel, PhD, MHS
256Publications
9,833Citations
Myelodysplastic Syndromes
Neoplasms
Leukemia
Myeloproliferative Disorders
Chronic Disease
Lymphoma
Publications
2026
Demographic, birth, parental characteristics, and the risk of early-onset colorectal cancer: A population-based nested case-control study in California.
Siddique S, Wang R, Berardi D, Johnson CH, Wiemels JL, Metayer C, Ma X. Demographic, birth, parental characteristics, and the risk of early-onset colorectal cancer: A population-based nested case-control study in California. Cancer 2026, 132: e70458. PMID: 42324895, DOI: 10.1002/cncr.70458.Peer-Reviewed Original ResearchThis study investigates early-onset colorectal cancer, showing male sex, Hispanic ethnicity, high birthweight, and older paternal age increase risk, while foreign-born mothers may reduce it.Prostate-Specific Membrane Antigen Imaging and Initial Treatment for Prostate Cancer
Leapman M, Rothen J, Long J, Kim I, Mitchell A, Yu J, Dinan M, Gross C, Ma X. Prostate-Specific Membrane Antigen Imaging and Initial Treatment for Prostate Cancer. JAMA Oncology 2026, 12 PMID: 42096231, PMCID: PMC13154023, DOI: 10.1001/jamaoncol.2026.0893.Peer-Reviewed Original ResearchThis study investigates how PSMA-PET imaging for prostate cancer leads to earlier use of advanced therapies compared to traditional bone scans, impacting treatment decisions and costs.IP80-11 ASSOCIATION BETWEEN PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING AND INITIAL TREATMENT FOR PROSTATE CANCER AMONG COMMERCIAL INSURANCE BENEFICIARIES
Leapman M, Rothen J, Long J, Kim I, Mitchell A, Yu J, Dinan M, Gross C, Ma X. IP80-11 ASSOCIATION BETWEEN PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING AND INITIAL TREATMENT FOR PROSTATE CANCER AMONG COMMERCIAL INSURANCE BENEFICIARIES. Journal Of Urology 2026, 215: e1589. DOI: 10.1097/01.ju.0001191764.50307.1e.11.Peer-Reviewed Original ResearchAcute myeloid leukemia after myeloproliferative neoplasms: Real‐world outcomes in the new treatment era in the United States
Bewersdorf J, Wang R, Mendez L, Mina A, Aguirre L, Stahl M, Zeidan A, Ma X, Podoltsev N. Acute myeloid leukemia after myeloproliferative neoplasms: Real‐world outcomes in the new treatment era in the United States. Cancer 2026, 132: e70415. PMID: 42033416, DOI: 10.1002/cncr.70415.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBridged Bicyclo Compounds, HeterocyclicFemaleHematopoietic Stem Cell TransplantationHumansLeukemia, Myeloid, AcuteMaleMiddle AgedMyeloproliferative DisordersRetrospective StudiesSulfonamidesTreatment OutcomeUnited StatesConceptsAcute myeloid leukemiaPost-MPN acute myeloid leukemiaLower-intensity therapiesAllo-HCTOverall survivalIntensive chemotherapyMyeloproliferative neoplasmsMyeloid leukemiaPatients treated with intensive chemotherapyProgression to acute myeloid leukemiaComplications of myeloproliferative neoplasmsAllogeneic hematopoietic cell transplantationTreatment of acute myeloid leukemiaMedian overall survivalBCL2 inhibitor venetoclaxHematopoietic cell transplantationEffective bridging therapyOutcomes of patientsInhibitor venetoclaxCurative optionHypomethylating agentsBridging therapyAML patientsCell transplantationTreatment eraResponse by Chu et al to Letter Regarding Article, “Joint Exposure to Ozone and Temperature and Acute Myocardial Infarction Among Adults Aged 18 to 64 Years in the United States”
Chu L, Ma X, Chen K. Response by Chu et al to Letter Regarding Article, “Joint Exposure to Ozone and Temperature and Acute Myocardial Infarction Among Adults Aged 18 to 64 Years in the United States”. Circulation 2026, 153: e914-e915. PMID: 41802023, DOI: 10.1161/circulationaha.125.078382.Commentaries, Editorials and LettersAdoption and Regional Variation of Prostate-Specific Membrane Antigen Positron Emission Tomography in the United States.
Leapman M, Long J, Westvold S, Rabil M, Sprenkle P, Kim I, Spilberg G, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Rivera D, Kluetz P, Karnes R, Dinan M, Mitchell A, Kunst N, Wang S, Ma X, Gross C. Adoption and Regional Variation of Prostate-Specific Membrane Antigen Positron Emission Tomography in the United States. JCO Oncology Practice 2026, op2500617. PMID: 41632928, DOI: 10.1200/op-25-00617.Peer-Reviewed Original ResearchThis study investigates the rapid adoption of PSMA-PET imaging for prostate cancer in the U.S., highlighting increased usage since 2021 and disparities based on income and education.Smoldering multiple myeloma in the United States: a population-based analysis
Wang S, Wang R, Schoen M, Huber J, Feuer E, Ruhl J, Neparidze N, Ma X, Davidoff A, Chang S. Smoldering multiple myeloma in the United States: a population-based analysis. Blood Advances 2026, 10: 661-664. PMID: 41213002, PMCID: PMC12870838, DOI: 10.1182/bloodadvances.2025017817.Peer-Reviewed Original ResearchAltmetricResidential proximity to active and abandoned oil and gas development and risk of childhood Ewing sarcoma in California
Clark C, Johnson N, Wang R, Stewart E, Spector L, Wiemels J, Metayer C, Deziel N, Ma X. Residential proximity to active and abandoned oil and gas development and risk of childhood Ewing sarcoma in California. Environmental Health 2026, 25: 12. PMID: 41535920, PMCID: PMC12888232, DOI: 10.1186/s12940-025-01259-3.Peer-Reviewed Original ResearchCitationsAltmetricConceptsSarcoma riskControls frequency-matched to casesHispanic childrenFrequency-matched to casesOdds ratioCalifornia Cancer RegistryClustering of cancerConfidence intervalsPediatric cancer riskNon-Hispanic childrenMultivariate logistic regressionBirth addressCancer RegistryHealth outcomesEwing sarcomaNon-HispanicCancer riskChildhood cancerResidential proximityBirth yearUnexposed childrenLogistic regressionMethodsThis studyExposure disparitiesDiagnosis of Ewing's sarcomaTrends in Smoldering Myeloma Incidence in the United States From Cancer Registries, 2012–2022
Wang R, Davidoff A, Schoen M, Huber J, Feuer E, Ruhl J, Neparidze N, Ma X, Chang S, Wang S. Trends in Smoldering Myeloma Incidence in the United States From Cancer Registries, 2012–2022. American Journal Of Hematology 2026, 101: 923-925. PMID: 41528052, PMCID: PMC12912868, DOI: 10.1002/ajh.70202.Commentaries, Editorials and LettersAltmetric
2025
The impact of Indigenous American-like ancestry on the risk of acute lymphoblastic leukemia in Hispanic/Latino children
Langie J, Chan T, Yang W, Kang A, Morimoto L, Stram D, Mancuso N, Ma X, Metayer C, Lupo P, Rabin K, Scheurer M, Wiemels J, Yang J, de Smith A, Chiang C. The impact of Indigenous American-like ancestry on the risk of acute lymphoblastic leukemia in Hispanic/Latino children. Human Genetics And Genomics Advances 2025, 7: 100534. PMID: 41261530, PMCID: PMC12664375, DOI: 10.1016/j.xhgg.2025.100534.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsAcute lymphoblastic leukemia riskRisk of acute lymphoblastic leukemiaHispanic/Latino childrenNon-genetic correlationsHighest incidences of acute lymphoblastic leukemiaAssociated with ALL riskGenetic etiologyGenetic etiology of diseaseRisk allelesGenetic risk lociFrequency of risk allelesIncidence of acute lymphoblastic leukemiaAdmixture mappingHispanic/Latino individualsAssociation signalsRisk lociRacial/ethnic groupsChildhood cancerSocioeconomic indicatorsGenetic ancestryHigher incidenceAcute lymphoblastic leukemiaGenetic variantsALL riskEffect size
News
Copy Link
News
- April 27, 2026Source: News Medical LIfe Sciences
Early life exposure to PFAS associated with common childhood leukemia
- January 27, 2026
Epidemiologist Dr. Magdalena Cerdá joins YSPH as Chair of the Department of Chronic Disease Epidemiology
- October 28, 2025Source: Yale News
Study Reveals Demographic Disparities in Uptake of Colorectal Cancer Screenings
- September 10, 2025Source: STAT
Risk of dying from chronic disease in the U.S. declined, but there are caveats, study says
Get In Touch
Copy Link
Contacts
Email
Academic Office Number
Office Fax Number
Mailing Address
Chronic Disease Epidemiology
PO Box 208034, 60 College Street
New Haven, CT 06520-8034
United States
Locations
60 College Street
Academic Office
Ste 406
New Haven, CT 06510